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Introduction
Bladder cancer is the fifth most frequent cancer in Europe. 
In 2012, its incidence and annual mortality rate were 
estimated to 151,200 and 51,400 cases, respectively [1]. 
Approximately 30% of these patients suffered from 
muscle- invasive bladder cancer (MIBC) at the time of 
initial diagnosis [2]. Radical cystectomy (RC) is the gold 
standard to treat these patients. In contrast to patients 
with nonmuscle- invasive bladder cancer (NMIBC), MIBC 
patients are subject to a high risk of relapse following 
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Abstract
To improve the clinical decision- making regarding further treatment manage-
ment and follow- up scheduling for patients with muscle- invasive bladder cancer 
(MIBC) after radical cystectomy (RC), a better prediction accuracy of prognosis 
for these patients is urgently needed. The objective of this study was to evaluate 
the validity of differentially expressed microRNAs (miRNAs) based on a previ-
ous study as prognostic markers for overall survival (OS) after RC in models 
combined with clinicopathological data. The expression of six miRNAs (miR- 
100- 5p, miR- 130b- 3p, miR- 141- 3p, miR- 199a- 3p, miR- 205- 5p, and miR- 214- 3p) 
was measured by RT- qPCR in formalin- fixed, paraffin- embedded tissue samples 
from 156 MIBC patients who received RC in three urological centers. Samples 
from 2000 to 2013 were used according to their tissue availability, with follow- 
up until June 2016. The patient cohort was randomly divided into a training 
(n = 100) and test set (n = 56). Seventy- three samples from adjacent normal 
tissue were used as controls. Kaplan–Meier, univariate and multivariate Cox 
regression, and decision curve analyses were carried out to assess the association 
of clinicopathological variables and miRNAs to OS. Both increased (miR- 130b- 
3p and miR- 141- 3p) and reduced (miR- 100- 5p, miR- 199a- 3p, and miR- 214- 3p) 
miRNA expressions were found in MIBC samples in comparison to nonmalignant 
tissue samples (P < 0.0001). miR- 199a- 3p and miR- 214- 3p were independent 
markers of OS in Cox regression models with the significant clinicopathological 
variables age, tumor status, and lymph node status. The prediction model with 
the clinicopathological variables was improved by these two miRNAs in both 
sets. The predictive benefit was confirmed by decision curve analysis. In conclu-
sion, the inclusion of both miRNAs into models based on clinical data for the 
outcome prediction of MIBC patients after RC could be a valuable approach 
to improve prognostic accuracy.
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In order to remedy this unsatisfactory situation, seri-
ous efforts have recently focused on new therapeutic 
strategies regarding the application of neoadjuvant and 
adjuvant chemotherapies [3]. A better risk assessment 
of patients has been recommended by developing novel 
predictive/prognostic models [4]. In clinical practice, the 
therapeutic management of these patients has so far been 
performed almost exclusively on the basis of clinical data 
and classical pathological TNM criteria but with few 
reliable results [4]. There is the hope that the identifica-
tion of new molecular tissue biomarkers could help to 
stratify risk groups and determine which patients benefit 
from adjuvant strategies after surgery [5]. While the 
results of numerous studies using immunohistochemical 
biomarkers have been rather disappointing regarding their 
clinical utilization [6], recent reports on gene- based 
approaches [5, 7, 8], including using microRNAs (miR-
NAs) as a new class of mRNA regulators seem to be 
much more promising [9–17].
In a previous study, we identified numerous new 
differentially expressed miRNAs in fresh- frozen bladder 
cancer tissue samples in comparison to normal adjacent 
tissue [18]. It was therefore the objective of this study 
to evaluate from these 15 previously described miRNAs 
the usefulness of the most promising miRNAs regarding 
their potential predictive ability of overall survival (OS) 
and assess their benefit in comparison to conventional 
clinicopathological variables in MIBC patients after RC. 
Criteria for the selection of these miRNAs in this study 
were determinations in a well measurable Cq range 
and at least twofold median expression differences 
between the nonmalignant and MIBC tissue samples 
to allow robust measurements as described before [18]. 
According to these criteria, both three up- regulated 
(miR- 130b- 3p, miR- 141- 3p, and miR- 205- 5p) and three 
down- regulated (miR- 100- 5p, miR- 199a- 3p, and miR- 
214- 3p) miRNAs were included in this study. To simulate 
the conditions of clinical practice formalin- fixed, 
paraffin- embedded (FFPE) tissue samples from three 




This study included 156 MIBC patients without any 
neoadjuvant therapy who underwent RC at three uro-
logical centers from 2000 to 2013. Sixty- four patients 
(41%) received adjuvant cisplatin- based chemotherapy 
after RC (Table 1). Follow- up data collected until June 
2016 were based on medical records and telephone con-
tact with the patients’ urologists and patients or family 
members and death certificates. The study was approved 
by the Hospital Ethics Committee (EA1/153/07; 
EA1/134/12) in accordance with the Declaration of 
Helsinki. The new STARD and REMARK guidelines were 
considered [19, 20].
The study was carried out on FFPE tissue specimens 
selected according to their tissue availability and follow- up 
data (Table 1). All samples were finally reviewed by an 
expert uropathologist (EK) according to the criteria of 
the International Union Against Cancer and the World 
Health Organization/International Society of Urological 
Pathology, as previously reported [18].
RNA­extraction­and­quantitative­RT-­PCR­of­
miRNAs
Previously described analytical procedures were applied 
[18, 21]. Hematoxylin/eosin staining was used to identify 
tumor areas with >80% tumor cells and nonmalignant 
areas. The areas of interest were punch- biopsied with a 
1- mm needle device and extracted with the miRNeasy 
FFPE Kit with an additional DNase I digestion step 
(Qiagen, Hilden, Germany). RT- qPCR measurements and 
normalizations were performed for the quantification of 
the miRNAs with TaqMan miRNA assays (Applied 
Biosystems, Foster City; Table S1) on a Light Cycler 480 
Instrument (Roche Diagnostics, Mannheim, Germany) as 
previously described including the related documentation 
with regard to the specific items of the MIQE guidelines 
[18, 21, 22].
Statistical­analysis
QBasePLUS, v.3.0 software (Biogazelle, Zwijnaarde, 
Belgium) was used for the analysis of RT- qPCR data. 
Statistical analyses were performed with SPSS 23 (SPSS 
Inc., Chicago) and MedCalc 16.8.4 (MedCalc Software, 
Ostend, Belgium). Nonparametric statistical tests 
(Spearman rank correlation, Mann- Whitney U test, 
Kruskal–Wallis test) were used. The discriminating capacity 
of miRNAs was assessed by receiver operating character-
istics (ROC) analysis and binary logistic regression. Kaplan–
Meier and Cox regression analyses were performed for 
OS. Decision curve analysis and time- dependent ROC 
analysis using the statistical approach of cumulative case/
dynamic control and incident case/dynamic control ROC 
analysis were used to assess the predictive benefit and 
accuracy of the examined markers [23, 24]. The SPSS 
bias- corrected and accelerated bootstrap method was used 
for the internal validation using the patient cohort by 
splitting at random into a training (n = 100) and test 
set (n = 56). P- values <0.05 (two- tailed) were considered 
statistically significant.
2254 © 2017 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. 
T. H. Ecke et al.Survival Prediction of Bladder Cancer by microRNAs
Results
Study­design­and­patient­characteristics
This retrospective study from three urologic depart-
ments included 156 MIBC patients that were randomly 
divided into a training (n = 100) and test set (n = 56). 
For comparison purposes, 73 nonmalignant tissue sam-
ples available from these patients were used as controls. 
The characteristics of the study groups are summarized 
in Table 1. There were no statistically significant dif-
ferences in age and sex between the controls and MIBC 
patients and between the training and test set with 




The expression data of the six miRNAs of interest (miR- 
100- 5p, miR- 130b- 3p, miR- 141- 3p, miR- 199a- 3p, 
miR- 205- 5p, miR- 214- 3p) were not statistically different 
(P = 0.084–0.792) between the three centers, so merged 
data could be evaluated. Figure 1 shows that the miRNA 
expressions differed with high statistical significance 
(P < 0.0001) between nonmalignant and MIBC samples 
except miR- 205- 5p. Both increased (miR- 130b- 3p, miR- 
141- 3p) and reduced levels (miR- 100- 5p, miR- 199a- 3p, 
miR- 214- 3p) were found in MIBC samples in comparison 
to nonmalignant tissue samples (P < 0.0001). The dif-
ferential miRNA expressions corresponded to the capacity 
of the miRNAs to discriminate between nonmalignant 
and MIBC tissue with miR- 130b- 3p as the best discrimi-




Correlations were not observed between all miRNAs and 
sex or age in nonmalignant and tumor samples (rs = 0.108–
0.001, P- values of 0.180–0.915). The clinicopathological 
Table 1. Clinicopathological characteristics of the study groups.
Variable Controls1 (n = 73) All MIBC patients 
(n = 156)





Age [year, median (range)] 69 (44–81) 69 (37–82) 0.689 69 (37- 82) 68 (45–81) 0.283
Gender (n; %) 0.401 0.241
Female 7 (10) 23 (15) 12 (12) 11 (20)
Male 66 (90) 133 (85) 88 (88) 45 (80)
pT status (n; %)
pT2 47 (30) 32 15 0.759
pT3 78 (50) 48 30
pT4 31 (20) 20 11
Grade (n; %)
G2 14 (9) 10 4 0.463
G3 140 (90) 88 52
G4 2 (1) 2 - 
pN status (n; %)
pN0/Nx 102 (65) 69 33 0.222
pN1 54 (35) 31 23
Adjuvant therapy (n; %)
Yes 64 (41) 43 21 0.611
No 92 (59) 57 35
Sample source (n; %)3
Center 1 51 (70) 101 (65) 0.486 62 39 0.598
Center 2 7 (10) 24 (15) 16 8
Center 3 15 (20) 31 (20) 22 9
Follow- up after surgery
Time [month; median (range)] 28 (1–180) 34 (1–180) 23 (1–163) 0.503
Death events (n; %) 99 (63) 67 (67) 32 (57) 0.230
Survival time [month, median (95% CI)] 34 (24–49) 35 (24–49) 26 (16–106) 0.589
CI, confidence interval; G, histopathological grade; MIBC, muscle- invasive bladder cancer; pN, lymph node status; pT, pathological tumor 
classification.
1Controls refer to nonmalignant tissue samples obtained from MIBC patients as described in Methods and Materials.
2Statistical tests: Mann–Whitney U test; Chi- square or Fisher’s exact test, and log- rank test, Kaplan–Meier analysis.
3Center 1: Campus Benjamin Franklin, University Hospital Charité; Center 2: Campus Mitte, University Hospital Charité; Center 3: Helios Clinical 
Center, Bad Saarow.
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variables pT status, histopathological grade, and lymph 
node status were also not significantly associated with all 
miRNAs (rs = 0.113–0.004, P-values of 0.160–0.957) except 
for miR- 130b- 3p and miR- 205- 5p to grade (rs = 0.236 
to −0.197, P- values of 0.003 and 0.014). These missing 
associations of miRNAs to clinicopathological variables 
corresponded to results obtained by the Kruskal–Wallis 
(pT status, histological grade) and Mann–Whitney test 
(lymph node status). Different correlation coefficients 
between miRNAs were observed between nonmalignant 




The differential expression and the different correlations 
between the examined miRNAs indicate their potential 
as prognostic markers. To substantiate the relationship 
between the clinical outcome of patients and the clinico-
pathological variables as well as miRNAs, OS was analyzed 
as the primary clinical endpoint since reliable information 
about cancer death was not available in all cases. OS was 
Figure 1. Differential expression of miRNAs (A: miR-100-5p; B: miR-130-3p; C: miR-141-3p; D: miR-199-3p; E: miR-205-5p; F: miR-214-3p) in 
nonmalignant bladder tissue (n = 73) and muscle- invasive bladder cancer (MIBC) tissue samples (n = 156). Expression values were normalized against 
the reference miRNA signature (miR- 101- 3p, miR- 148b- 5p, miR- 125a- 5p, and miR- 151- 5p) as previously described [21]. Medians and interquartile 
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defined as the time from the date of RC until the time 
of death or the last follow- up.
Kaplan–Meier survival analyses of clinicopathological 
variables showed a decreased OS depending on the lymph 
node metastasis, increased pT status, and age, but OS 
was not associated with adjuvant chemotherapy 
(Fig. S2). These initial data proved the representative-
ness of the study cohort to evaluate the impact of 
miRNAs regarding their usefulness as prognostic markers. 
For the internal validation of data, the prognostic per-
formance of all clinicopathological variables and the six 
miRNAs was calculated using the training and test set 
(Table 2). The variables with P- values <0.10 in univari-
able analyses for clinicopathological factors (age, pT 
status, pN status) and for the two miRNAs miR- 199a- 3p, 
miR- 214- 3p were used to build up two models, a full 
model with all five variables and a reduced model after 
a backward elimination approach (Table 2). This 
threshold of P- value <0.10 was selected to avoid a pos-
sible false negative decision (Type II error) for a potential 
relevant parameter using a low alpha value in this first 
step of model building based on univariable Cox regres-
sion analysis. Both miRNAs also remained as statistically 
independent variables in the model after backward elimi-
nation. In addition, the training and test set gave closely 
corresponding results, indicating that an overfitting bias 
of results can be largely excluded. It is of a special 
interest that the above mentioned miR- 130b- 3p as the 
best discriminator between malignant and nonmalignant 
bladder tissue failed to provide any prognostic informa-
tion (Table 2).
To confirm the prognostic impact of miR- 199- 3p and 
miR- 214- 3p, C- statistics were performed in a model with 
the three above- mentioned relevant clinicopathological 
variables alone (Model CR- 1) in comparison to a model 
(Model CR- 2) that also included the relevant miR- 199a- 3p 
Table 2. Cox proportional hazard regression analyses of clinicopathological factors and miRNAs for predicting overall survival in MIBC patients after 
radical cystectomy in training and test set1.
Variable2 Training set (n = 100) Test set (n = 56)
HR (95% CI) P-value HR (95% CI) P-value
Univariable analysis
Age (<69/≥69 years) 1.56 (0.94–2.53) 0.087 1.98 (0.99–3.97) 0.055
Sex (female/male) 1.61 (0.73–3.53) 0.283 1.20 (0.45–3.62) 0.659
pT status (pT2,3,4) 1.46 (1.04–2.04) 0.029 1.64 (0.83–3.44) 0.098
Grade (G2/G3- 4) 0.96 (0.46–2.01) 0.904 1.50 (0.29–23.9) 0.529
pN status (N0,Nx/N1) 2.01 (1.23–3.28) 0.005 1.96 (0.94–4.65) 0.053
Adjuvant therapy 1.38 (0.85–2.22) 0.193 0.89 (0.44–1.79) 0.741
miR- 100- 5p 0.99 (0.87–1.23) 0.853 0.93 (0.60–1.12) 0.680
miR- 130b- 3p 0.99 (0.77–1.27) 0.918 1.02 (0.53–1.85) 0.643
miR- 141- 3p 0.93 (0.70–1.25) 0.633 0.76 (0.39–1.24) 0.306
miR- 199a- 3p 0.53 (0.30–0.91) 0.023 0.49 (0.18–0.96) 0.042
miR- 205- 5p 1.02 (0.92–1.14) 0.720 1.16 (0.81–1.95) 0.302
miR- 214- 3p 1.80 (1.12–2.89) 0.015 2.96 (1.29–6.75) 0.005
Multivariable analysis, full model3
Age 1.49 (0.88–2.51) 0.137 1.65 (0.77–3.53) 0.255
pT status 1.45 (1.01–2.07) 0.045 1.85 (0.99–3.43) 0.053
pN status 1.62 (0.97–2.71) 0.064 2.26 (1.01–5.04) 0.046
miR- 199a- 3p 0.57 (0.32–1.02) 0.058 0.32 (0.11–0.94) 0.039
miR- 214- 3p 1.79 (1.12–2.85) 0.015 3.30 (1.11–9.77) 0.031
Multivariable analysis, backward elimination4
pT status 1.42 (1.01–1.98) 0.042 1.81 (0.96–3.39) 0.065
pN status 1.67 (1.01–2.77) 0.052 2.32 (1.06–5.09) 0.035
miR- 199a- 3p 0.53 (0.27–0.89) 0.026 0.35 (0.13–0.91) 0.032
miR- 214- 3p 1.88 (1.21–3.51) 0.005 3.29 (1.24–8.74) 0.017
CI, confidence interval; G, histopathological grading; HR, hazard ratio; MIBC, muscle- invasive bladder cancer; miR, microRNA; pT, pathological tumor 
classification; pN, lymph nodal status.
1The training set included 100 and the test set 56 of MIBC patients randomly selected from the cohort characterized in Table 1.
2Calculations were performed by bootstrapping (2000 resamples) for clinical variables using categorized data as indicated in brackets and for miRNAs 
using normalized continuous expression values.
3The multivariable analysis included all variables with P-values <0.10 obtained in the univariable analysis to avoid a type II error in the first step of 
model building.
4The backward multivariable analysis (P = 0.05 for entry; P = 0.10 for removal) was based on the five variables used in the full multivariable analysis. 
The 95% CI of the hazard ratios and the P- values of the final model were obtained after bootstrapping (2000 resamples).
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and miR- 214- 3p (Table 2). Based on the median survival 
time of about 3 years in the entire cohort (Table 1), the 
AUCs in cumulative case/dynamic and incident case/
dynamic control ROC analyses were calculated (Fig. 2A 
and C). Both approaches resulted in statistically significant 
higher AUC values in the miRNA- enriched model in 
comparison to the model with clinicopathological variables 
alone (AUC of 0.735 vs. 0.645 and 0.709 vs. 0.622; Fig. 2A 
and C). The predictive benefit of the two miRNAs is also 
shown in the decision curve analyses (Fig. 2B and D). 
The curves of the model with miRNAs (Model CR- 2) 
are always above the curves of the model with only the 
clinicopathological variables (Model CR- 1).
Discussion
In this retrospective study exclusively focused on the out-
come OS, we continued to translate our conclusions drawn 
from previous miRNA studies in fresh- frozen tissue samples 
into clinical practice using archived tissue FFPE samples 
from three centers [18, 21]. This study design follows 
the concept of a discovery- driven global strategy for 
Figure 2. Improved survival predictive accuracy by including miR- 199a- 3p and miR- 214- 3p (Model CR- 2) in a model with only clinicopathological 
variables age, pT status, and lymph node metastasis (Model CR- 1). Areas under the time- dependent ROC curve (AUC) of the two models were 
calculated based on (A) a cumulative case (n = 78)/dynamic control (n = 41) approach at 36 months after surgery as well as on (C) an incident case 
(n = 99)/dynamic control (n = 57) approach [24]. AUCs of Model CR- 2 showed statistically significant higher values in both approaches in comparison 
with Model CR- 1 [Model CR- 2 vs. Model CR- 1 in (A) with 0.735 (0.624–0.827) vs. 0.645 (0.545–0.746), P = 0.031 and in (C) with 0.709 (0.637–
0.796) vs. 0.622 (0.534–0.716), P = 0.011]. Curves in the decision curve analysis confirmed (B and D) the benefit of including the two miRNAs in the 
model based only on clinicopathological variables.
2258 © 2017 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. 
T. H. Ecke et al.Survival Prediction of Bladder Cancer by microRNAs
biomarker search in translational research [25, 26]. It is 
a hypothesis- generating approach that considers the com-
plex situation in clinical settings with regard to all possible 
variables which could influence the selected clinical end 
point. We previously postulated four development phases 
of biomarker assays for clinical practice, namely, first, the 
discovery and selection of potential biomarkers, second, 
the assay setup and performance control, third, the vali-
dation by clinical assessment, and finally the validation 
by clinical usability [27]. According to this scheme, we 
would classify our present study into the third phase. 
The study results suggest that miR- 199a- 3p and miR- 214- 3p 
are helpful biomarkers to enhance the OS prediction in 
comparison with clinicopathological data alone in MIBC 
patients after RC and improve therefore further decision- 
making both for clinicians and patients.
Numerous miRNA studies in bladder cancer identified 
histological grade and pT classification dependent miR 
expressions and proved typical miRNA alterations related 
to the two divergent pathways found in the development 
of NMIBC and MIBC (reviewed by Guancial et al. [28]). 
As already noted in the introduction, only a few studies 
used miRNAs as prognostic and predictive biomarkers in 
bladder cancer patients but mostly in NMIBC patients 
[9–17]. Different miRNAs were suggested as prognostic 
biomarkers for MIBC patients as combinations of four 
(let- 7c, miR- 125b- 1, miR193a, miR- 99a) [17], three (miR- 
9, miR- 183, miR- 200b) [13], and two miRNAs (miR- 143, 
miR- 145) [15], but also as predictive markers for the 
response to cisplatin- based adjuvant chemotherapy [11]. 
However, none of these studies performed multivariable 
analyses or verified the examined miRNAs as independent 
markers.
In a recent study, Schubert et al. summarized the incon-
sistent data situation of miRNAs as prognostic markers 
in urological tumors [29]. Different strategies to identify 
suitable prognostic miRNAs, the use of various analytical 
techniques, the insufficient sample size of study groups 
with lack of internal/external validations and multivariable 
analyses are reasons for the partially contradictory results 
if miRNAs have been applied as prognostic biomarkers 
in bladder cancer [29]. Furthermore, beside the applica-
tion of different clinical endpoints, studies have been also 
performed in cohorts including both MIBC and NMIBC 
patients without separate data evaluation or missing mul-
tivariable analysis [16, 30]. Distinct molecular alterations 
including different miRNA profiles in noninvasive and 
invasive tumors may facilitate discrimination between both 
bladder cancer entities [9, 31, 32], but this aspect needs 
a special attention for the prognostic assessment of miR-
NAs. The different miRNA expression, partly characterized 
by an opposite expression between nonmalignant, NMIBC, 
and MIBC tissue as for example in the case of miR- 141 
and miR- 205 [18], could hamper a reliable prediction of 
the clinical outcome in multivariable Cox regression analy-
ses in connection with clinicopathological factors. This 
possible bias was impressively illustrated by the example 
of miR- 214 [33]. This miRNA was shown to be an inde-
pendent factor of recurrence- free survival and OS in the 
MIBC cohort but failed if MIBC and NMIBC patients 
were analyzed as a combined group. To avoid all these 
possible errors, we studied only one bladder cancer entity, 
MIBC patients. We used FFPE samples from the practical 
point of view with a sufficient sample size and number 
of events for carrying out multivariable analyses, and 
performed a twofold internal validation approach by using 
a training and test set with bootstrapping calculation of 
continuous instead of categorized data according to the 
REMARK guidelines to achieve a high level of statistical 
power.
The up- and down- regulated expression of the six 
selected miRNAs primarily found in fresh- frozen MIBC 
versus nonmalignant tissue in our previous study [18] 
was confirmed in the FFPE samples in this study reaching 
at least by a median twofold change, except for miR- 
205- 5p (Fig. 1). Moreover, three points should be empha-
sized in relation to assessment of outcome as the main 
aim of this study: the missing or only weak correlations 
of miRNAs with the clinicopathological risk factors, the 
different correlation coefficients among the miRNAs 
described in the Results, and the failure of miR- 130- 3p 
as the best miRNA discriminator between nonmalignant 
and malignant tissue to provide any prognostic informa-
tion. The striking hallmark of the uncorrelated differential 
expression of miRNAs to known disease variables char-
acterizes the miRNAs here examined as potential orthogonal 
biomarkers [34]. This particular feature of orthogonal 
markers appears as a precondition that such markers can 
influence the clinical endpoint of OS independent of the 
conventional clinicopathological variables and must there-
fore be included as necessary independent variables in a 
corresponding prognostic model. The evidence of such 
an independent variable in multivariable analysis addition-
ally promotes the discovery of novel downstream targets 
and their associated pathways [34]. Our study proved 
that both miR- 199a- 3p and miR- 214- 3p remained such 
independent variables in multivariable Cox regression 
models (Table 2). The predictive accuracy of OS probability 
based only on the conventional clinicopathological vari-
ables could be improved by these two miRNAs. This 
clinical benefit was verified by the decision curve analysis 
and also by the time- dependent ROC analysis if the two 
miRNAs were included into the model with only con-
ventional clinicopathological variables (Fig. 2). The com-
bined use of the clinicopathological variables and the 
expression data of the two microRNAs measured in tissue 
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samples from cystectomy specimens offers the opportunity 
to develop a risk scoring system in prospective studies 
as result of the clinical usability of this approach. This 
would correspond to the final development phase of bio-
marker assay for clinical practice as suggested above [27]. 
In contrast to miR- 199a- 3p and miR- 214- 3p, miR- 130b- 3p 
as the best discriminator between nonmalignant and cancer 
tissue did not offer any prognostic information. The prog-
nostic information could also not be confirmed for miR- 
141- 3p and miR- 205- 5p, which were previously shown 
only in Kaplan–Meier analyses, but not in multivariable 
Cox regression analyses [16, 18]. The reason might be 
that both miRNAs show an opposite expression in NMIBC 
and MIBC and the mentioned studies were performed in 
combined cohorts of NMIBC and MIBC patients.
Up to now there are only few investigations concerning 
the role of miR- 199a- 3p and miR- 214- 3p with special 
focus on bladder cancerogenesis and its neoplastic pro-
gression. miR- 199a derives from two loci of the human 
genome, mir- 199a- 1 of chromosome 19 (cytogenetic loca-
tion 19p13.2) and mir- 199a- 2 of chromosome 1 (cytoge-
netic location 1q24.3). These two loci encode mir- 199a, 
which generate the two mature miRNAs, miR- 199a- 3p 
and miR- 199a- 5p. Depending on the underlying malig-
nancy, miR- 199a- 3p acts both as oncogene being up- 
regulated like in gastric and colorectal cancer [35, 36] 
and as tumor suppressor being down- regulated like in 
renal cell cancer, hepatocellular carcinoma, prostate cancer 
or bladder cancer [37–39]. The down- regulated expression 
of miR- 199a- 3p in bladder cancer was also described as 
tumor suppressive miRNA by other groups but not further 
evaluated as prognostic marker [31, 32, 40, 41]. After we 
had finished our study, Sakaguchi et al. [42] recently 
showed that the expression of all four miR- 199 family 
members consisting of miR- 199b- 3p, and miR- 199b- 5p 
in addition to the two above- mentioned miR- 199a forms, 
was down- regulated in bladder cancer. The decreased 
expression of the miRNAs was found to be associated 
with a poor OS of patients shown in Kaplan–Meier analyses 
but it was not additionally assessed in multivariable Cox 
regression analyses [42]. It was shown that these miRNAs 
act as tumor suppressors by targeting ITGA3 (integrin 
subunit α3). However, the increased ITGA3 mRNA expres-
sion was not significantly associated with the survival of 
patients [42]. This phenomenon of missing link between 
a differentially expressed miRNA and its verified target 
gene with regard to a clinical endpoint is understandable, 
bearing in mind that miR- 199a targets numerous genes 
that could affect the prognosis of patients. For example, 
miR- 199a- 3p was validated as tumor suppressive miRNA 
in other cancers like prostate cancer targeting AURKA 
(aurora kinase A) [39], in renal cell cancer GSK3B (gly-
cogen synthase kinase 3 beta) [37], and in hepatocellular 
carcinoma HGF (hepatocyte growth factor), MMP2 (matrix 
metallopeptidase 2), VEGFA (vascular endothelial growth 
factor A), and its corresponding receptors [43]. So far, 
these targets have not been examined in bladder cancer 
as potential points of action for miR- 199a- 3p. However, 
all these genes play a significant role in signaling pathways 
of angiogenesis, invasion, and metastasis in cancer as 
shown in the software DIANA- mirPath (http://diana.imis.
athena-innovation.gr/DianaTools) [44]. Moreover, it is of 
particular interest that the second relevant prognostic 
mature miRNA in our study, miR- 214- 3p, derives from 
the stem loop sequence of mir- 214 that clusters with mir- 
199a- 2 of the same chromosome locus 1q24.3. Similar to 
miR- 199a- 3p, miR- 214- 3p acts, depending on the cancer 
types, oncogenic in osteosarcoma and oral cancer [45, 
46] but tumor suppressive in breast, cervical, esophageal, 
and bladder cancers [33, 47–51]. Based on our previous 
expression study [18], Wang et al. [33] characterized the 
down- regulated miR- 214- 3p as a suppressive miRNA. This 
miRNA functions as an independent factor of OS in MIBC 
patients, targeting the oncogene PDRG1 (p53 and DNA 
damage regulated 1). SLC34A2 (solute carrier family 34 
member 2) and several genes of the epithelial- mesenchymal 
transition and the NGAL/MMP-9 (lipocalin 2/metallopepti-
dase 9) pathways were also verified or predicted to be 
negatively regulated by miR- 214- 3p in the process of 
bladder cancer development [50, 51].
The possible biological significance of the co- expression 
of the two down- regulated miR- 199a and miR- 214 was 
shown in testicular germ cell tumor [52]. A self- regulatory 
network of the two microRNAs together with PSMD10 
(proteasome 26S subunit, non- ATPase 10), TP53 (tumor 
protein p53), and DNTM1 (DNA methyltransferase 1) was 
identified whose dysfunction results in tumor progression. 
As mentioned above, these two microRNAs also act as 
regulators of numerous target genes that have been already 
validated so far in urinary bladder and other solid cancers 
(target characteristics are given in Table S4). Moreover, 
based on our data of prognostic relevance of miR- 199a- 3p 
and miR- 214- 3p, the view is supported that such a regula-
tory network or at least a cooperative action of the micro-
RNAs as shown in other cancer examples [53] could also 
exist in bladder cancer. A detailed investigation of the 
functional role of the two miRNAs would be worthwhile 
but was beyond the scope of this study. On the other 
hand, we share the view of Burke [54] that the functional 
role of biomarker might be, in a certain sense, useful to 
explain the biological rationale of biomarker but is not 
decisive for its clinical usability. Under this translational 
aspect, the primary focus in the search for a truly reliable 
biomarker has to be directed more toward the clinical 
benefit of the potential new biomarker in comparison to 
the so far used procedures in clinical practice.
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Limitations of the study are, despite our precautions 
for bias- free analyses using the internal validation by a 
training and test sets with bootstrapping, its retrospective 
nature on overall and not cancer- specific survival, the 
lack of external validation, and the biomarker- focused 
aspect without elucidating the molecular mechanisms as 
argued above.
Conclusions
In summary, our study identified miR- 199a- 3p and miR- 
214- 3p as independent prognostic biomarkers for the 
prediction of OS in MIBC patients after RC. Their inclu-
sion in prognostic models based on relevant clinicopatho-
logical risk factors improved the predictive accuracy. Such 
enhanced information of combined clinicopathological and 
molecular data could support clinicians in their decision- 
making in the treatment management and follow- up 
scheduling after RC. It could also help patients who wish 
to be kept fully informed about their further life expec-
tancy to plan and manage their remaining lifetime. Thus, 
further efforts through complimentary multicenter pro-
spective randomized studies would be worth to translate 
these biomarkers into clinical practice as suggested.
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